Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.920
-0.140 (-6.80%)
At close: Feb 21, 2025, 4:00 PM
1.980
+0.060 (3.13%)
After-hours: Feb 21, 2025, 7:58 PM EST
Editas Medicine Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 8.08, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 320.83% from the current stock price of 1.92.
Analyst Consensus: Buy
* Price targets were last updated on Dec 16, 2024.
Analyst Ratings
The average analyst rating for Editas Medicine stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 4 | 4 | 4 |
| Buy | 0 | 1 | 1 | 2 | 2 | 2 |
| Hold | 7 | 6 | 6 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +160.42% | Dec 16, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Dec 16, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +108.33% | Dec 13, 2024 |
| Barclays | Barclays | Hold Maintains $5 → $3 | Hold | Maintains | $5 → $3 | +56.25% | Dec 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 13, 2024 |
Financial Forecast
Revenue This Year
32.85M
from 78.12M
Decreased by -57.96%
Revenue Next Year
8.49M
from 32.85M
Decreased by -74.16%
EPS This Year
-2.73
from -2.02
EPS Next Year
-1.49
from -2.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 76.0M | 44.1M | 36.2M | |||
| Avg | 32.8M | 8.5M | 9.4M | |||
| Low | 1.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.7% | 34.3% | 326.9% | |||
| Avg | -58.0% | -74.2% | 11.1% | |||
| Low | -97.8% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.31 | -0.80 | -0.67 | |||
| Avg | -2.73 | -1.49 | -1.36 | |||
| Low | -3.14 | -2.13 | -2.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.